Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Perrotti A"'
Autor:
Vincenzo Dattilo, Cristina Barbara Spoleti, Giuseppe Perrotti, Nicola Costa, Nicola Perrotti, Claudia Vincenza Fiumara, Rodolfo Iuliano, Rosario Amato, Francesca Musumeci, Domenica Scumaci, Lucia D'Antona, Silvia Schenone, Giovanni Cuda, Giada Catalogna, Rossana Tallerico
Publikováno v:
Translational Oncology
Translational Oncology, Vol 12, Iss 8, Pp 1045-1055 (2019)
Translational Oncology, Vol 12, Iss 8, Pp 1045-1055 (2019)
Ovarian cancer is the second most common gynecological malignancy worldwide. Paclitaxel is particularly important in the therapy of ovarian carcinomas, but the treatment efficacy is counteracted by the development of resistance to chemotherapy. The i
Autor:
Daniela Petriella, Nicola Silvestris, Francesco Leonetti, Stefania Tommasi, Giuseppe Badalamenti, Rosamaria Pinto, Oronzo Brunetti, Vito Longo, Livia Fucci, Simona De Summa, Angela Calabrese, Katia Danza, Domenico Galetta, Antonella Argentiero, Pia Perrotti
Publikováno v:
Cancers, Vol 11, Iss 6, p 749 (2019)
Cancers
Cancers
The management of multiple primary cancers, an event not so infrequent in oncology practice, is a critical issue due to the lack of literature. In this study, we reported the case of a patient with non-small cell metastatic lung cancer (NSCLC) and pa
Autor:
Corrado Spatola, Giada Maria Vecchio, Antonio Di Cataldo, Salvatore Perrotti, Dorotea Bosco, Rosalia Latino
Publikováno v:
World Journal of Surgical Oncology, Vol 17, Iss 1, Pp 1-6 (2019)
World Journal of Surgical Oncology
World Journal of Surgical Oncology
Background Neuroendocrine tumors are a group of rare neoplasms, and the pancreatic neuroendocrine tumors (PNETs) represent only 1–2% of all pancreatic malignant tumors. The most common sites of these tumors include the gastrointestinal tract, lung,
Autor:
Livia Fucci, Nicola Silvestris, Pia Perrotti, Oronzo Brunetti, Francesco Leonetti, Katia Danza, Giuseppe Badalamenti, Antonella Argentiero, Simona De Summa, Daniela Petriella, Vito Longo, Rosamaria Pinto, Angela Calabrese, S. Tommasi
Management of multiple primary cancers, a not so infrequent event in oncology practice, is a critical issue due to the lack of literature . In this study, we reported the case of a patient with metachronous double metastatic non small cell lung cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72a3001636637e13f638f99e50840785
https://doi.org/10.20944/preprints201905.0173.v1
https://doi.org/10.20944/preprints201905.0173.v1
Autor:
Mariapaola Fina, Monica Tani, Enrico Derenzini, Pier Luigi Zinzani, Michele Baccarani, Gerardo Musuraca, Umberto Vitolo, Vittorio Stefoni, Stefano Fanti, Alessio Perrotti
Publikováno v:
Cancer. 112:856-862
BACKGROUND A prospective, single-arm, open-label, nonrandomized Phase 2 study of combined fludarabine and mitoxantrone (FM) plus radioimmunotherapy was conducted to evaluate efficacy and safety in patients with untreated, indolent, nonfollicular non-
Autor:
Roberto Palumbo, Claudio Romani, Pasquale Niscola, Claudio Cartoni, Marco Giovannini, Luca Cupelli, Gisella Vischini, Giovanni Del Poeta, Paolo de Fabritiis, Laura Scaramucci, Gregorio Antonio Brunetti, Francesco Bondanini, Alessio Perrotti, Andrea Tendas, Michele Ferrannini
Publikováno v:
Expert Review of Anticancer Therapy. 11:415-432
The management of hematological malignancies (HM) in renally impaired patients may be a difficult task. Indeed, the kidney represents a major elimination pathway for many chemotherapeutic agents and their metabolites, whose serum levels are not usual
Autor:
Lapo Alinari, Luciano Guardigni, Marco Gobbi, Alessandra Tucci, Vito Michele Lauta, Sergio Storti, Simona Soverini, Anna Lia Molinari, Stefano Pileri, Alessio Perrotti, Brunangelo Falini, Pier Paolo Fattori, Pier Luigi Zinzani, Amalia De Renzo, Michele Baccarani, Fabrizio Ciccone, Alessandro Pulsoni, Sante Tura, Maurizio Martelli, Patrizia Gentilini, Francesco Zaja
PurposePromising new therapeutic options for follicular lymphoma (FL) include fludarabine plus mitoxantrone (FM) and the mouse/human anti-CD20 antibody, rituximab. We performed a randomized comparative trial of FM with cyclophosphamide, doxorubicin,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::079bcb1a1cac319d8d197394b37bc0e2
http://hdl.handle.net/11585/2868
http://hdl.handle.net/11585/2868
Autor:
Sante Tura, Vittorio Stefoni, Lapo Alinari, Giuseppe Visani, Monica Tani, Pier Luigi Zinzani, Luciano Guardigni, Stefano Pileri, Anna Lia Molinari, Nicoletta Villivà, Michelle Baccarani, Francesca Bonifazi, Alessandro Pulsoni, Patrizia Gentilini, Alessio Perrotti, Maurizio Martelli
Publikováno v:
Leukemia & Lymphoma. 45:1815-1819
In the last years, fludarabine (FLU) alone or in combination with other drugs has been reported to be effective in the treatment of previously untreated low-grade non-Hodgkin's lymphomas (LG-NHL). We report on the therapeutic efficacy and toxicity of
Autor:
Nicola Di Renzo, Ignazio Majolino, Gino Santini, Paolo Vivaldi, Corrado Tarella, Teodoro Chisesi, Alberto De Crescenzo, Giuseppe Fioritoni, Marco Sorio, Carola Boccomini, Maurizio Martelli, Marco Ladetto, Alessio Perrotti, Maurizio Musso, Maura Brugiatelli, Sonia Vallet, P. Coser, Daniela Drandi, R Zambello, Fabio Benedetti, S. Morandi, Umberto Vitolo, Flavia Salvi, Monica Astolfi, Paolo Corradini, Andrea Gallamini, Alessandro Pileri
Publikováno v:
Blood. 100:1559-1565
Single-center experiences have shown that intensified treatments with autologous transplantation are a promising therapeutic strategy for patients with high-risk follicle-center lymphoma (FCL) at diagnosis, whereas data from prospective multicenter t
Autor:
Maria Paola Fina, Filippo Venturini, Michele Baccarani, Alessandro Broccoli, Alessio Perrotti, Vittorio Stefoni, Letizia Gandolfi, Pier Luigi Zinzani, Maurizio Martelli, Francesco Zaja, Stefano Pileri, Amalia De Renzo, Enrico Derenzini, Maria Concetta Petti, Cinzia Pellegrini
Young patients (aged 18-60 years) with good-prognosis diffuse large B-cell lymphoma (DLBCL) [0 and 1 risk factor according to age-adjusted international prognostic index (aa-IPI)] are distinguished from patients with poor-prognosis. Six cycles of cyc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e9ffffc157c05ec7ba3af32084db6b1
http://hdl.handle.net/11585/84116
http://hdl.handle.net/11585/84116